Vascular ATP-dependent potassium channels, nitric oxide, and human forearm reactive hyperemia.

Vascular ATP-dependent potassium (K+ATP) channels open and contribute to reactive hyperemia (RH) in animals. The contribution of K+ATP channels to ischemic vasolidation during RH and interactions with endothelium-derived nitric oxide have not been well characterized in human subjects. RH blood flow responses (mL/dL) following 5 minutes of cuff occlusion were measured using strain-gauge plethysmography in 22 normal human subjects age 42 +/- 2 years. Measurements were obtained at baseline and following intra-arterial administration of the K+ATP channel closer glibenclamide, the nitric oxide synthase inhibitor L-N-monomethyl arginine (L-NMMA), or both drugs simultaneously. Glibenclamide (100 micrograms/min) did not change basal flow (2.7 +/- 0.3 to 2.7 +/- 0.3 mL/min/dL), but L-NMMA (8 mumol/min) and combined glibenclamide and L-NMMA significantly (p < 0.05) decreased basal flow (3.0 +/- 0.5 to 2.0 +/- 0.2 and 3.3 +/- 0.5 to 2.5 +/- 0.3, respectively). Glibenclamide significantly (p < 0.01) decreased RH flow (18.2 +/- 1.3 to 14.8 +/- 1.3) and excess flow (5.3 +/- 1.2 to 1.3 +/- 1.3). L-NMMA significantly (p < 0.05) decreased RH flow (21.2 +/- 1.8 to 18.9 +/- 1.9) and tended to decrease excess flow (6.1 +/- 2.2 to 3.9 +/- 2.5). Combined drug infusion significantly (p < 0.1) decreased RH flow (21.6 +/- 2.2 to 18.0 +/- 2.4) and excess flow (6.3 +/- 1.6 to 1.6 +/- 1.6), with reductions in RH and excess flow similar to those following glibenclamide infusion alone. We conclude that forearm vascular K+ATP channels are closed at baseline. They open and contribute to RH vasodilation. The addition of nitric oxide inhibition to K+ATP channel blockade does not result in additive or synergistic inhibition of RH.

Testosterone and frailty.

Although estrogen replacement therapy has become well established in the management of postmenopausal women, most physicians pay much less attention to the testosterone status of their older male patients. There is now increasing evidence that testosterone deficiency-Low Testosterone Syndrome-occurs in older men and is associated with decreased muscle strength and bone density, as well as memory problems. This article reviews the evidence for the existence of Low Testosterone Syndrome, often characterized as the male menopause or viropause, and the emerging evidence that testosterone therapy may ameliorate some of the symptoms and signs of frailty in men beyond 50 years of age.

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

A decline in testicular function is recognized as a common occurrence in older men. However data are sparse regarding the effects of hypogonadism on age-associated physical and cognitive declines. This study was undertaken to examine the year-long effects of testosterone administration in this patient population. Fifteen hypogonadal men (mean age 68 +/- 6 yr) were randomly assigned to receive a placebo, and 17 hypogonadal men (mean age 65 +/- 7 yr) were randomly assigned to receive testosterone. Hypogonadism was defined as a bioavailable testosterone <60 ng/dL. The men received injections of placebo or 200 mg testosterone cypionate biweekly for 12 months. The main outcomes measured included grip strength, hemoglobin, prostate-specific antigen, leptin, and memory. Testosterone improved bilateral grip strength (P < 0.05 by ANOVA) and increased hemoglobin (P < 0.001 by ANOVA). The men assigned to testosterone had greater decreases in leptin than those assigned to the control group (mean +/- SEM: -2.0 +/- 0.9 ng/dL vs. 0.8 +/- 0.7 ng/dL; P < 0.02). There were no significant changes in prostate-specific antigen or memory. Three subjects receiving placebo and seven subjects receiving testosterone withdrew from the study. Three of those seven withdrew because of an abnormal elevation in hematocrit. Testosterone supplementation improved strength, increased hemoglobin, and lowered leptin levels in older hypogonadal men. Testosterone may have a role in the treatment of frailty in males with hypogonadism; however, older men receiving testosterone must be carefully monitored because of its potential risks.

Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure.

BACKGROUND: Patients with heart failure have reduced peripheral blood flow at rest, during exercise, and in response to endothelium-dependent vasodilators. Nitric oxide formed from L-arginine metabolism in endothelial cells contributes to regulation of blood flow under these conditions. A randomized, double-blind crossover study design was used to determine whether supplemental oral L-arginine can augment peripheral blood flow and improve functional status in patients with moderate to severe heart failure. METHODS AND RESULTS: Fifteen subjects were given 6 weeks of oral L-arginine hydrochloride (5.6 to 12.6 g/d) and 6 weeks of matched placebo capsules in random sequence. Compared with placebo, supplemental oral L-arginine significantly increased forearm blood flow during forearm exercise, on average from 5.1 +/- 2.8 to 6.6 +/- 3.4 mL. min-1. dL-1 (P < .05). Furthermore, functional status was significantly better on L-arginine compared with placebo, as indicated by increased distances during a 6-minute walk test (390 +/- 91 versus 422 +/- 86 m, P < .05) and lower scores on the Living With Heart Failure questionnaire (55 +/- 28 versus 42 +/- 26, P < .05). Oral L-arginine also improved arterial compliance from 1.99 +/- 0.38 to 2.36 +/- 0.30 mL/mm Hg (P < .001) and reduced circulating levels of endothelin from 1.9 +/- 1.1 to 1.5 +/- 1.1 pmol/L (P < .05). CONCLUSIONS: Supplemental oral L-arginine had beneficial effects in patients with heart failure. Further studies are needed to confirm the therapeutic potential of supplemental oral L-arginine and to identify mechanisms of action in patients with heart failure.

Assay of mixtures of padimate-O and oxybenzone in sunscreen formulations by high-performance liquid chromatography.

A simple assay method for the quality control of some sunscreen products containing padimate-O and oxybenzone has been developed. A methanolic extract of the product containing sulfathiazole internal standard was subjected to reversed-phase high-performance liquid chromatography on a 10-micron Partisil ODS-2 column with methanol-acetonitrile (90:10, v/v) mobile phase. The drug-sulfathiazole peak height ratio was linear between 0.04-2.68 micrograms of padimate-O (r = 1.0003) and 0.02-1.05 micrograms of oxybenzone (r = 0.9997) injected. All peaks were well-resolved. Approximate retention times for sulfathiazole, oxybenzone and padimate-O were 3.9, 5.7 and 7.4 min., respectively. The height equivalent to a theoretical plate (+/- S.D.) were (n = 10) 0.79 +/- 0.07, 0.53 +/- 0.06 and 0.26 +/- 0.04 mm, for sulfathiazole, oxybenzone and padimate-O, respectively. Average percent recoveries (+/- S.D.) (n = 3) from simulated lotions containing 7% padimate-O and 3% oxybenzone were: padimate-O, 101.4 +/- 1.5%; oxybenzone 99.9 +/- 1.9%; from simulated lipsticks containing (a) 7% padimate-O and 3% oxybenzone: 103.8 +/- 1.2% and 100.1 +/- 0.9%, respectively; and (b) 7% padimate-O and 0.5% oxybenzone: 99.4 +/- 0.6% and 99.3 +/- 2.4%, respectively. The method was successfully applied to marketed products.